The aim of this retrospective cross-sectional study was to assess the usefulness of phosphase and tensin homolog deleted on chromosome 10 (PTEN) and p53 protein immunoexpression in predicting the risk of malignancy in endometrial polyps. The study was conducted at tertiary public hospital, university teaching center, and private practice clinic.
Introduction
The endometrium undergoes a series of changes throughout the menstrual cycle. The histopathologic patterns of endometrial diseases widely range from atrophy to cancer, with polyps being very common. [1] Endometrial polyps are focal circumscribed overgrowths of the endometrial mucosa, usually of the basal portion, which protude into the uterine cavity. [2, 3] The etiopathogenesis of polyps is still unclear, and their incidence is increased among women aged 40 to 60 years. [4] [5] [6] [7] Polyps can be diagnosed using imaging technology (ultrasonography, hysterosonography, hysteroscopy, and magnetic resonance), with hysteroscopy being the main procedure used for diagnosis and treatment. [8] [9] [10] [11] Signs and symptoms of endometrial polyps include abdominal pain, irregular menses, dysmenorrhea, abnormal uterine bleeding (abnormally heavy or prolonged flow, intermenstrual bleeding, and spotting), leucorrhea, and bleeding during intercourse. [12] Adenocarcinoma, with a background of atypical hyperplasia in various degrees, is the most common form of malignancy found in endometrial polyps. [13] [14] [15] [16] [17] [18] Other risk factors for malignancy in endometrial polyps include systemic hypertension, type 2 diabetes mellitus (DM), obesity, and prolonged time since menopause. [19] [20] [21] [22] Uterine polyps have gained considerable attention in immunohistochemical studies, especially from those aiming at assessing their malignant potential. [14, [23] [24] [25] [26] Several studies using markers for cell cycle control in carcinogenesis, particularly p53 and phosphase and tensin homolog deleted on chromosome 10 (PTEN) have been conducted.
The objective of this study was to assess the usefulness of PTEN and p53 protein immunoexpression in predicting the risk of malignant transformation in endometrial polyps, and thus contribute for the development of new therapies for treatment.
Methods
This cross-sectional study was based on chart data from a convenience sample of patients diagnosed with endometrial polyps who underwent hysteroscopy followed by polypectomy at the Gynecologic Endoscopy and Family Planning Unit of the Gynecology Discipline of Botucatu Medical School, São Paulo State University-SP, and Abrão Clinic in Marília-SP, Brazil, between January 2010 and December 2014. Approval from the institutional Committee of Research Ethics was obtained on October 6, 2014 under number 820.385.
A total of 159 patients were allocated into 2 groups: Group A, 120 patients with endometrial polyps without atypia; and Group B, 39 patients with endometrial polyps with atypia restricted to the polyp, who received conservative treatment.
Data collected included age, body mass index (BMI), number of gestations, smoking status, systemic arterial hypertension (SAH), presence of type 2 DM, and time since menopause.
Paraffin blocks with the most representative fragments of endometrial polyps were selected for the assessment of p53 and PTEN immunoexpression. The primary antibodies used were a PTEN mouse monoclonal antibody (Clone 28H6, NCL-PTEN, Novocastra, at 1:150) and mouse monoclonal p53 protein (clone DO-7 mouse, M7001, DAKO, at 1:3000). Both were detected using Envision FLEX (DAKO) ( Table 1 ). Deparaffinization at 65°C for 20 minutes, and antigen retrieval at 97°C for 20 minutes in high pH solution (Tris-EDTA pH 9.0) were performed using an automated system (PTLink, DAKO). Slides were then allowed to cool to 65°C and washed in Tris-buffered saline solution containing Tween 20, pH 7.6 (Envision Flex Wash Buffer) for 5 minutes. Peroxidase block was performed for 5 minutes in Envision Flex peroxidase block solution. After overnight incubation with primary antibodies, slides were washed for 5 minutes, incubated with EnVision FLEX/HRP (dextran polymer conjugated with horseradish peroxidase and secondary antibodies against mouse and rabbit immunoglobulins) for 20 minutes, and washed for another 5 minutes. Immunostaining was developed in a DAB plus chromogen solution (Envision Flex Substrate Working Solution -DAB plus hydrogen peroxide buffer solution) for 10 minutes. Finally, after rinsing in washing solution for 5 minutes, the slides were counterstained with Mayer hematoxylin, dehydrated in three xylol baths (2 minutes each), and mounted permanently (DAKO CS703). Appropriate positive and negative controls were used for each staining. The expression of each marker was determined by counting 500 cells over randomly selected high-power fields. Nuclear brown staining indicated positive expression when the percentage of cells stained was >10% and negative when the percentage of cells stained was <10% (Figs. 1 and 2 ).
For data analysis, quantitative variables were expressed as mean, standard deviation, median, and minimum/maximum values, whereas qualitative variables were described by absolute frequency and percentage. Qualitative variables were analyzed by the test of Goodman for contrasts among multinomial populations. Normally distributed quantitative variables were compared using parametric tests, namely the Student t test and 1-way analysis of variance. Not normally distributed quantitative variables were assessed using the nonparametric tests of MannWhitney and Kruskal-Wallis. Odds ratio (OR) and relative risk were calculated considering a 95% confidence interval and P < .05. Significance level for data analysis was set at 5%. [27, 28] 
Results
Groups A and B were divided into 4 subgroups each as follows: A1 (80 patients, 66.7%) p53À/PTEN+ immunostaining, A2 (20 patients, 16.7%) p53+/PTEN+ immunostaining, A3 (14 patients, 11.7%) p53+/PTENÀ immunostaining, A4 (6 patients, 5.0%) p53À/PTENÀ immunostaining; and B1 (21 patients, 53.8%) p53À/PTEN+ immunostaining, B2 (11 patients, 28.2%) p53 +/PTEN+ immunostaining, B3 (4 patients, 10.3%) p53+/PTENÀ immunostaining, and B4 (3 patients, 7.7%) p53À/PTENÀ immunostaining.
No significant differences were observed in clinical and epidemiologic parameters (BMI, number of gestations, smoking, SAH, type 2 DM, and time since menopause), indicating sample homogeneity, except for age. Mean age in group A (57.5, range of 40-89 years) significantly differed from that in group B (61, range of 40-82 years) (P = .0186). The incidence of malignant endometrial neoplasia was higher in group B than in group A (20.5% and 5.8%, respectively, P = .0113) ( Table 2) .
Among patients of subgroup A1 (normal staining patterns), only 1 showed neoplasia (1.25%), whereas in subgroups A2, A3, and A4 (at least 1 marker abnormally stained), 6 patients had neoplasia (15%): 2 in subgroup A2, 3 in subgroup A3, and 1 in subgroup A4 (Table 3) . Neoplasia was more frequent in patients with abnormal staining than in those with normal staining patterns (15% and 1.25%, respectively; P = .0089, OR = 13.94 [1.62; 120.27]). Table 3 Immunostaining, neoplasia rate, P-value, and odds ratio (OR) in subgroups A1, A2, A3, and A4. Among patients of subgroup B1 (normal staining patterns), there was only 1 with neoplasia (4.8%), while in subgroups B2, B3, and B4 (at least 1 marker abnormally stained), there were 7 patients with neoplasia (38.9%): 4 in subgroup B2, 2 in subgroup B3, and 1 in subgroup B4 ( Table 4 ). The incidence of malignant neoplasia in patients with abnormally stained markers was higher than in those normally stained (38.9% and 4.8%, respectively, P = .0255, OR = 12.73 [1.38; 117.27]).
In group A, p53 expression was negative in 86 patients, of whom 2 had neoplasia, and positive in 34 patients, of whom 5 showed neoplasia (P = .0296, OR = 7.24 [1.33; 39.38]) ( Table 5 ). In contrast, neoplasia was seen in 3 out of 100 patients with PTEN+ expression, and in 4 out of 20 with PTENÀ expression (P = .0147, OR = 8.08 [1.65; 39.55]) (Table 6) .
In group B, endometrial neoplasia was observed in 2 out of 24 patients with p53À expression, and in 6 out of 15 patients with p53+ (P = .0483, OR = 7.33 [1.24; 43.41]) (Table 5 ). In patients with PTEN+ expression, 5 out of 32 patients had neoplasia, whereas of 7 patients with PTENÀ expression, 3 showed neoplasia (P = .2715, OR = 4.05 [0.68; 23.90]) (Table 6 ).
Discussion
Endometrial polyps remain among the most enigmatic and poorly understood gynecologic diseases. The optimal treatment of these polyps remains controversial. Management with systematic polypectomy is still debatable as no consensus has been reached. Polyps usually occur in postmenopausal women, and their malignant potential is unknown. Thus, the purpose of this study was to assess the risk of malignant transformation in women with endometrial polyps.
As immunohistochemical markers can be useful to determine the risk of malignant transformation in endometrial polyps, both p53 and PTEN were used in this study. These markers were chosen because of the promising results obtained in prior studies evaluating each one of them alone. Furthermore, both p53 and PTEN mutations have been found in 50% to 70% of human malignant tumors in the bladder, brain, breast, uterine cervix, colon, rectum, esophagus, and thyroid. [29, 30] To our knowledge, the use of concomitant p53 and PTEN to assess malignancy risk in endometrial polyps remains unreported. This study compared the findings obtained with concomitant p53 and PTEN with Table 4 Immunostaining, neoplasia rate, P-value, and odds ratio (OR) in subgroups B1, B2, B3, and B4.
Group B (polyps with atypia)
Number of patients * Table 5 p53 expression, P-value, and odds ratio (OR) in subgroups A and B. 
The TP53 gene, named for the molecular mass of its protein product (a 53-kDa nuclear phosphoprotein containing 393 amino acids), was the first tumor suppressor gene to be identified in 1979. For about 10 years, TP53 was believed to be an oncogene, a cell cycle promoter. [31, 32] TP53 mutations (punctual or not) significantly alter the p53 protein. As a result, p53 loses the ability to stimulate cell cycle arrest and apoptosis. [33] Jia et al (2008) , in a total of 139 endometrial samples, found p53 mutations in 0%, 43%, 72%, and 96% in resting endometrium, endometrial glandular dysplasia, serous endometrial intraepithelial carcinoma, and endometrial serous carcinoma (ESC), respectively. Most of the lesions showed overexpression of p53 protein that was significantly correlated with TP53 gene mutation. They concluded that mutation of the TP53 gene is probably one of the most important factors to initiate the ESC. [29] Trahan et al (2005), evaluating the behavior of serous papillary carcinoma in endometrial polyps and the overexpression of p53 protein, observed a high p53 mutation rate in endometrial polyps. According to these authors, the high rate of protein p53 overexpression suggests that a TP53 gene mutation occurs early in the disease and might explain the rapid growth of the tumor. [34] The PTEN is another tumor suppressor that was isolated and sequenced in 1997. [30] PTEN is a 403-amino acid and dual lipid/ protein phosphatase which can modulate cell proliferation, cell cycle arrest, and cell apoptosis, migration, and adhesion. [35] Janiec-Jankowska et al (2010), in DNA isolated from 81 endometrial cancers, found mutations in TP53 and/or PTEN genes in 64.2% of the 81 endometrial cancers: in 16.1%, mutations occurred only in TP53; in 33.3%, only in PTEN; and in 14.8%, in both TP53 and PTEN genes. [36] Their results demonstrated that TP53 gene mutations occur in some of endometrioid endometrial cancers in the presence of PTEN gene mutations, suggesting that both these genes participate in the development of these tumors, with PTEN inactivation being one of the earliest events in endometrial carcinogenesis. [37] In this study, the group with endometrial polyps without atypia (group A), malignant endometrial neoplasia was found in 5.8% of patients, in agreement with prior reports. [34] The incidence of neoplasia significantly differed between patients with normal staining patterns and those with at least 1 marker abnormally stained (P = .0089, OR = 13.94 [1.62; 120.27] ). Whereas in subgroup A1 (normal staining patterns), malignant endometrial neoplasia was seen in only 1.25%, in the remaining A subgroups (A2 + A3 + A4), which showed abnormal staining, it was found in 15% of patients. Moreover, when both markers were abnormally stained (subgroup A3), 21.4% of patients showed neoplasia (P = .0063, OR = 21.55 [2.06; 225.80]). The rates of advanced age, hypertension, and diabetes in all A subgroups were high, consistently with data reported in the literature. [4, [19] [20] [21] [22] In group B (endometrial polyps with atypia), 20.5% of patients showed malignant endometrial neoplasia. In subgroup B1 (normal staining pattern), malignant neoplasia was seen in 4.8% of patients, similarly to previous reports. [6, 36] Among the patients of the remaining B subgroups (B2 + B3 + B4), neoplasia was found in 38.9%, which significantly differs from the rate observed in subgroup B1 (P = .0255, OR = 12.73 [1.38; 117.27] ). In subgroup B3 (both markers abnormally stained), malignant neoplasia was present in 50% of cases, but statistical significance was not reached (P = .0868, OR = 20.00 [1.21; 330.97]) probably due to the size of the sample.
Our results suggest that immunohistochemical analysis can be useful in cases of endometrial polyps, especially when associated with risk factors such as advanced age, high BMI, SAH, DM, and prolonged time since menopause. Comparison of most of our findings with those from previous research was limited by the lack of prior studies using p53 and PTEN concomitantly. [29, 36, 37] In brief, patients with endometrial polyps showing abnormal p53 and PTEN immunohistochemistry in the presence of the aforementioned risk factors were more likely to have malignant endometrial neoplasia requiring closer follow-up.
Conclusion
1. Immunohistochemical analysis can be useful to predict malignant transformation in cases of endometrial polyps. 2. Further larger studies to confirm the data obtained are warranted. 3. The risk of malignant endometrial neoplasia is higher in patients with endometrial polyps showing abnormal p53 and PTEN immunohistochemistry in the presence of advanced age. 4. The incidence of malignant endometrial neoplasia was higher in women of more advance age with polyps with atypia.
